CRD 3874
Alternative Names: CRD-3874; CRD3874-SILatest Information Update: 09 Oct 2024
At a glance
- Originator Curadev Pharma
- Developer Curadev Pharma; University of Maryland, Baltimore
- Class Antineoplastics; Small molecules
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Merkel cell carcinoma; Sarcoma
- Preclinical Solid tumours
Most Recent Events
- 26 Aug 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT06626633)
- 05 Apr 2024 Adverse events and pharmacodynamics data from preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 15 Feb 2024 Curadev Pharma receives approval from the US FDA for use of CRD 3874 in first-in-human studies in patients with advanced solid cancers